Home -> Law Blog Directory -> Legal Commentary Blogs -> Infamy or Praise
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
Find a Local Lawyer
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Legal Commentary
: Infamy or PraiseTGIBR: Thank God It's Blawg Review! (298)
On Valentine's Day, Tannebaum showed no love for the marketeers and gurus who have lately come to convince the more desperate, greedy, or unsuspecting amongst our numbers that social media offers a path to riches and respect. He is an unwavering opponent of these "social media snake oil salesmen" and has frequently turned a spotlight on their activities and questionable qualifications.
While Tannebaum's certainly been notable for his sharp tongue, Blawg Review #298 demonstrates another side as well. Apparent here is his respect for the true professionals in our profession — those who dedicate themselves to the highest ideals in the practice of law, who defend their clients' freedom and interests zealously, and who cultivate genuine skills rather than SEO-driven "expertise" to dupe the unwary.
Highlights of this week's Blawg Review include posts keeping track of real change in Egypt, discussing a well-deserved sanction for legal search term squatting, condemning a disturbing conflict of interest amongst the leadership of a criminal defense organization, and offering some sage advice to younger solo practitioners.
Jennifer Lubinski will host next week's Blawg Review at her Work Product blog.
Full post as published by Infamy or Praise on February 15, 2011 (boomark / email).
FDA Issues Update on Safety Review Orlistat
Orlistat FDA Issues Update on Safety Review
Aurora Loan Faces Class Action over Mortgage Review Services
Aurora Loan Faces Class Action over Mortgage Review Services
FDA Review of Prostate Cancer Treatment Prompts Warning of Risk for Diabetes
Prostate Cancer Treatment FDA Review Prompts Warning of Risk for Diabetes
Xigris
Study Prompts FDA Safety Review
Lipitor
Review of Studies Show No Significant Benefit in Women
Wrinkle-Fillers
FDA to Review Labeling due to Adverse Event Reports










